Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

6(85.7%)

Phase 2

1(14.3%)

7Total

Phase 1(6)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01485042Phase 1Completed

Dose Escalation Study of Pazopanib Plus TH-302

Role: lead

NCT00416637Phase 1Completed

Bevacizumab in Treating Patients With Advanced Solid Tumors

Role: lead

NCT00920868Phase 1Completed

XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib

Role: lead

NCT00888043Phase 1Completed

Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors

Role: lead

NCT00276575Phase 1Completed

Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors

Role: lead

NCT00586443Phase 1Completed

BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)

Role: lead

NCT00416494Phase 2Completed

Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Role: lead

All 7 trials loaded